The life sciences sector is one of a small number of knowledge-based industries that has the potential to drive economic growth in developed and emerging countries over the long term. As a result, there is increasing interest in the promotion and regulation of the sector at the national, continental, and global levels. Therefore, it will be increasingly important that the public policy team within a life sciences company develops and maintains coordinated global policy positions and that an integrated and coordinated approach to public policy analysis should draw on a common toolkit of argumentation and evidence that prevents waste and duplication. Vice President Tim Wilsdon explores the challenges to corporate policy positions for life sciences and discusses how CRA’s knowledge and experience can provide support in this most challenging arena. To read this article, click here:
Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...